Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | NEK2 | P51955 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5013 | 1.00 | KDM4E (0.52) | KDM4EMAPTALDH1A1NEK2KMT2A | |
| Potassium SCHEMBL30601760 | 0.97 | KDM4E (0.50) | KDM4EMAPTALDH1A1NEK2KMT2A | |
| SCHEMBL8742086 | 0.97 | KDM4E (0.50) | KDM4EMAPTALDH1A1NEK2KMT2A | |
| Piperazine SCHEMBL28080505 | 0.97 | KDM4E (0.50) | KDM4EMAPTALDH1A1NEK2KMT2A | |
| Hydrochloric Acid SCHEMBL311054 | 0.97 | KDM4E (0.50) | KDM4EMAPTALDH1A1NEK2KMT2A | |
| SCHEMBL92545 | 0.91 | KDM4E (0.56) | KDM4EMAPTALDH1A1NEK2KMT2A | |
| Piperidine SCHEMBL28145582 | 0.91 | KDM4E (0.56) | KDM4EMAPTALDH1A1NEK2KMT2A | |
| Methylene Chloride SCHEMBL16447276 | 0.91 | KDM4E (0.45) | KDM4EMAPTALDH1A1NEK2KMT2A | |
| Hydrochloric Acid SCHEMBL189869 | 0.89 | KDM4E (0.54) | KDM4EMAPTALDH1A1KMT2ALMNA | |
| SCHEMBL21040872 | 0.89 | KDM4E (0.54) | KDM4EMAPTALDH1A1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 357 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117794923-A | Benzodioxane compound, and preparation method and application thereof | 南京红云生物科技有限公司 | 2024-03-29 | — | — | CN | claimed |
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-10-05 | — | — | US | claimed |
| EP-4236942-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2023-09-06 | — | — | EP | claimed |
| EP-4236937-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2023-09-06 | — | — | EP | claimed |
| US-20230212147-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-07-06 | — | — | US | claimed |
| EP-4166553-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-04-19 | — | — | EP | claimed |
| CN-115916759-A | Substituted quinazoline compound, preparation method, pharmaceutical composition and application thereof | 南京红云生物科技有限公司 | 2023-04-04 | — | — | CN | claimed |
| WO-2023011610-A1 | BENZODIOXANE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 南京红云生物科技有限公司 | 2023-02-09 | — | — | WO | claimed |
| CN-115697996-A | Alkenyl pyrimidine compound, preparation method and application thereof | 南京红云生物科技有限公司 | 2023-02-03 | — | — | CN | claimed |
| US-20220280530-A1 | PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | Anhui Newstar Pharmaceutical Development Co., Ltd. (CN) | 2022-09-08 | — | — | US | claimed |
| EP-3424929-A1 | PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | Anhui New Star Pharmaceutical Development Co., Ltd (CN) | 2019-01-09 | — | — | EP | claimed |
| US-20180312508-A1 | PYRIMIDOPYRROLE COMPOUNDS, METHOD FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | XIAMEN UNIVERSITY (CN) | 2018-11-01 | — | — | US | claimed |
| EP-3290420-A1 | PYRIMIDINE PYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | Xiamen University (CN) | 2018-03-07 | — | — | EP | claimed |
| EP-3152210-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-04-12 | — | — | EP | claimed |
| CN-106188060-A | Pyrimido azoles, its preparation method, Pharmaceutical composition and application thereof | 厦门大学 | 2016-12-07 | — | — | CN | claimed |
| CN-105503837-A | Substitute quinazolines derivative with Aurora kinase inhibitory activity and application thereof | UNIV SUN YAT SEN | 2016-04-20 | — | — | CN | claimed |
| WO-2015187684-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-12-10 | — | — | WO | claimed |
| EP-1458393-B1 | SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-06-25 | — | — | EP | claimed |
| EP-1102789-A1 | MONOCYCLIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTION AND COMPOSITIONS CONTAINING THEM | Menarini Ricerche S.p.A. (IT) | 2001-05-30 | — | — | EP | claimed |
| WO-2000008046-A1 | MONOCYCLIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTION AND COMPOSITIONS CONTAINING THEM | MENARINI RICERCHE S.P.A. (IT) | 2000-02-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212147-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | WEE1, EGFR, WEE2 | KDM4E 3419/4885MAPT 2939/4885ALDH1A1 1742/4885 |
| US-20180312508-A1 | PYRIMIDOPYRROLE COMPOUNDS, METHOD FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | TPMT, DHPS, TYMP | KDM4E 1889/4885MAPT 3771/4885ALDH1A1 364/4885 |
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | KDM4E 3671/4885MAPT 2177/4885ALDH1A1 3822/4885 |
| US-20220280530-A1 | PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | MST1, MSTN, MST1R | KDM4E 4200/4885MAPT 1263/4885ALDH1A1 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.